Literature DB >> 6391456

Serratia: a problem in a neonatal nursery.

P Fitzgerald, J H Drew, I Kruszelnicki.   

Abstract

We have noted an increased incidence of Serratia species isolates in our Special Care Nursery recently and have reviewed our experience over the 7 year period from 1976 to 1982. Fifty newborn infants had strains of Serratia isolated, 30 of which were found in 1982. Two strains of Serratia species were isolated: Serratia marcescens in 46 newborn infants and Serratia liquefaciens in six, with both types being found in two infants. All isolates were sensitive initially to gentamicin, kanamycin sulphate, chloramphenicol and co-trimoxazole. However, resistance was documented subsequently to each of these antibiotics. Only 64% of isolates only were sensitive initially to ampicillin; 27% subsequently developed resistance. Recent isolates were sensitive to cefotaxime sodium. Twenty-nine infants (58%) were colonized, and 16 (32%) had minor infections such as conjunctivitis. However in five infants (10%) life threatening illness occurred. Of the five infants with serious infection two had meningitis and three were septicaemic; one infant died. In both infants with meningitis difficulty was experienced in eradicating the organism and porencephaly developed in both.

Entities:  

Mesh:

Year:  1984        PMID: 6391456     DOI: 10.1111/j.1440-1754.1984.tb00079.x

Source DB:  PubMed          Journal:  Aust Paediatr J        ISSN: 0004-993X


  2 in total

1.  Biofilm Formation and Quorum-Sensing-Molecule Production by Clinical Isolates of Serratia liquefaciens.

Authors:  Sara Remuzgo-Martínez; María Lázaro-Díez; Celia Mayer; Maitane Aranzamendi-Zaldumbide; Daniel Padilla; Jorge Calvo; Francesc Marco; Luis Martínez-Martínez; José Manuel Icardo; Ana Otero; José Ramos-Vivas
Journal:  Appl Environ Microbiol       Date:  2015-03-06       Impact factor: 4.792

Review 2.  Serratia infections: from military experiments to current practice.

Authors:  Steven D Mahlen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.